Fig. 2

Estimated OS (a) and TFS (b) for thalassemia patients receiving UD-HSCT and the OS (c) and TFS (d) for patients receiving MSD-HSCT in the NCR and CCR groups
Estimated OS (a) and TFS (b) for thalassemia patients receiving UD-HSCT and the OS (c) and TFS (d) for patients receiving MSD-HSCT in the NCR and CCR groups